milrinone has been researched along with Subarachnoid Hemorrhage in 39 studies
Subarachnoid Hemorrhage: Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The preventative effect of cisternal irrigation with milrinone against vasospasm was evaluated in 12 patients with subarachnoid hemorrhage (SAH) of World Federation of Neurosurgical Societies grade IV or V treated between September 1999 and September 2000." | 9.11 | Milrinone reduces cerebral vasospasm after subarachnoid hemorrhage of WFNS grade IV or V. ( Arakawa, Y; Goto, Y; Hashimoto, N; Hojo, M; Kikuta, K; Nozaki, K; Yamagata, S, 2004) |
| "There is currently only very low quality evidence to support the use of milrinone to improve important outcomes in patients with delayed cerebral ischemia secondary to subarachnoid hemorrhage." | 8.95 | The Use of Milrinone in Patients with Delayed Cerebral Ischemia Following Subarachnoid Hemorrhage: A Systematic Review. ( Guichon, C; Lannes, M; Teitelbaum, J; Zeiler, F, 2017) |
| "Intravenous and intra-arterial milrinone as a rescue measure for delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH) has been adopted by several groups, but so far, evidence for the clinical benefit is unclear and effect on brain perfusion is unknown." | 8.12 | Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine-based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Andereggen, L; Berberat, J; Ensner, R; Marbacher, S; Remonda, L; Steiger, HJ, 2022) |
| "The role of nimodipine and milrinone in the management of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH) was studied using clinical and TCD (transcranial Doppler) parameters." | 8.12 | Role of Nimodipine and Milrinone in Delayed Cerebral Ischemia. ( Chakrabarti, D; Konar, SK; Kotwal, A; Radhakrishnan, M; Ramalingaiah, AH; Shukla, D; Srinivasaiah, B; Sundaram, M, 2022) |
| "Milrinone has emerged as an option to treat delayed cerebral ischemia after subarachnoid hemorrhage." | 7.91 | Which Protocol for Milrinone to Treat Cerebral Vasospasm Associated With Subarachnoid Hemorrhage? ( Chiron, C; Crespy, T; Francony, G; Heintzelmann, M; Payen, JF; Tahon, F; Vinclair, M, 2019) |
| "We compared the physiological dose response of dobutamine and milrinone in patients with subarachnoid hemorrhage requiring a pulmonary artery catheter." | 7.73 | Dobutamine versus milrinone after subarachnoid hemorrhage. ( Commichau, C; Connolly, ES; Du, Y; Fitzsimmons, BF; Kreiter, KT; Lavine, SD; Mayer, SA; Naidech, A; Parra, A, 2005) |
| "It is suggested that milrinone was effective and safe for the treatment of cerebral vasospasm after subarachnoid hemorrhage in the patients in this series." | 7.71 | Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: report of seven cases. ( Arakawa, Y; Goto, Y; Hojo, M; Ishii, A; Kikuta, K; Yamagata, S, 2001) |
| "Several methods have been used to treat cerebral vasospasm, which is a major cause of morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage (SAH)." | 6.76 | Angiographic evaluation of the effect of intra-arterial milrinone therapy in patients with vasospasm from aneurysmal subarachnoid hemorrhage. ( Deus-Silva, L; dos Santos, MP; Lum, C; Shankar, JJ, 2011) |
| "Delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage continues to be associated with high levels of morbidity and mortality." | 6.72 | Treatment of Subarachnoid Hemorrhage-associated Delayed Cerebral Ischemia With Milrinone: A Review and Proposal. ( Abulhasan, YB; Angle, MR; Aziz-Sultan, MA; Bernier, TD; Chung, DY; Dasenbrock, H; Du, R; Feske, S; Henderson, GV; Izzy, S; Leslie-Mazwi, TM; Nelson, SE; Patel, N; Schontz, MJ, 2021) |
| "Delayed cerebral ischemia (DCI) is a complication of aneurysmal subarachnoid hemorrhage (aSAH) and is associated with significant morbidity and mortality." | 5.91 | Subarachnoid Hemorrhage, Delayed Cerebral Ischemia, and Milrinone Use in Canada. ( Almojuela, A; Bokhari, R; Christie, SD; Duda, T; Eagles, ME; Elkaim, LM; Iorio-Morin, C; Kameda-Smith, MM; Lownie, SP; MacLean, MA; Persad, ARL; Rizzuto, MA; Teitelbaum, J, 2023) |
| "OBJECTIVE Delayed cerebral ischemia (DCI) is an important complication after aneurysmal subarachnoid hemorrhage (aSAH)." | 5.48 | Effect of intrathecal milrinone injection via lumbar catheter on delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Chin, M; Fukuda, H; Handa, A; Koyanagi, M; Kurosaki, Y; Lo, B; Sadamasa, N; Uezato, M; Yamagata, S, 2018) |
| "Although cerebral vasospasm remains a common complication of SAH and constitutes an important predictor of outcome, in the setting of PNSAH, it is extremely rare." | 5.46 | Basilar artery vasospasm after pretuncal non-aneurysmal subarachnoid hemorrhage responding to milrinone. ( Alamri, AS; Alturki, AY; Badawy, MM; Lo, BW, 2017) |
| "Acute cerebral hypoperfusion following subarachnoid hemorrhage (SAH) is highly related to the pathogenesis of delayed cerebral ischemia (DCI), but the therapeutic option is poorly available." | 5.46 | Neurocardiac protection with milrinone for restoring acute cerebral hypoperfusion and delayed ischemic injury after experimental subarachnoid hemorrhage. ( Ishikawa, T; Mutoh, T; Nakamura, K; Sasaki, K; Taki, Y; Tatewaki, Y, 2017) |
| "DIND, delayed cerebral infarction (DCI), and modified Rankin scale at 3 months after SAH were used for the assessment of outcome." | 5.40 | Milrinone via lumbar subarachnoid catheter for vasospasm after aneurysmal subarachnoid hemorrhage. ( Chin, M; Narumi, O; Sadamasa, N; Yamagata, S; Yoshida, K, 2014) |
| "For the treatment of cerebral vasospasm, current therapies have focused on increasing blood flow through blood pressure augmentation, hypervolemia, the use of intra-arterial vasodilators, and angioplasty of proximal cerebral vessels." | 5.38 | Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol. ( Angle, M; Cardoso, M; del Pilar Cortés, M; Lannes, M; Teitelbaum, J, 2012) |
| "Milrinone was injected intracisternally (0." | 5.36 | Effect of vasodilation by milrinone, a phosphodiesterase III inhibitor, on vasospastic arteries after a subarachnoid hemorrhage in vitro and in vivo: effectiveness of cisternal injection of milrinone. ( Date, I; Hishikawa, T; Iseda, K; Manabe, H; Nishiguchi, M; Ono, S, 2010) |
| "Attempts to reverse cerebral vasospasm (CVS) after aneurysmal subarachnoid hemorrhage (aSAH) rely on a limited number of treatments." | 5.35 | Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. ( Cholley, BP; Fraticelli, AT; Losser, MR; Payen, D; Saint Maurice, JP, 2008) |
| "The preventative effect of cisternal irrigation with milrinone against vasospasm was evaluated in 12 patients with subarachnoid hemorrhage (SAH) of World Federation of Neurosurgical Societies grade IV or V treated between September 1999 and September 2000." | 5.11 | Milrinone reduces cerebral vasospasm after subarachnoid hemorrhage of WFNS grade IV or V. ( Arakawa, Y; Goto, Y; Hashimoto, N; Hojo, M; Kikuta, K; Nozaki, K; Yamagata, S, 2004) |
| "There is currently only very low quality evidence to support the use of milrinone to improve important outcomes in patients with delayed cerebral ischemia secondary to subarachnoid hemorrhage." | 4.95 | The Use of Milrinone in Patients with Delayed Cerebral Ischemia Following Subarachnoid Hemorrhage: A Systematic Review. ( Guichon, C; Lannes, M; Teitelbaum, J; Zeiler, F, 2017) |
| "Intravenous and intra-arterial milrinone as a rescue measure for delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH) has been adopted by several groups, but so far, evidence for the clinical benefit is unclear and effect on brain perfusion is unknown." | 4.12 | Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine-based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Andereggen, L; Berberat, J; Ensner, R; Marbacher, S; Remonda, L; Steiger, HJ, 2022) |
| "The role of nimodipine and milrinone in the management of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH) was studied using clinical and TCD (transcranial Doppler) parameters." | 4.12 | Role of Nimodipine and Milrinone in Delayed Cerebral Ischemia. ( Chakrabarti, D; Konar, SK; Kotwal, A; Radhakrishnan, M; Ramalingaiah, AH; Shukla, D; Srinivasaiah, B; Sundaram, M, 2022) |
| "Milrinone has emerged as an option to treat delayed cerebral ischemia after subarachnoid hemorrhage." | 3.91 | Which Protocol for Milrinone to Treat Cerebral Vasospasm Associated With Subarachnoid Hemorrhage? ( Chiron, C; Crespy, T; Francony, G; Heintzelmann, M; Payen, JF; Tahon, F; Vinclair, M, 2019) |
| "We conducted a single-center, retrospective review of consecutive patients with clinically symptomatic vasospasm after aneurysmal subarachnoid hemorrhage that failed medical management with "triple H therapy" and subsequently received intraarterial nicardipine and/or milrinone between March 2005 and July 2007." | 3.76 | Hemodynamic management and outcome of patients treated for cerebral vasospasm with intraarterial nicardipine and/or milrinone. ( Bittner, E; Marota, JJ; Pivi, S; Schmidt, U, 2010) |
| "We compared the physiological dose response of dobutamine and milrinone in patients with subarachnoid hemorrhage requiring a pulmonary artery catheter." | 3.73 | Dobutamine versus milrinone after subarachnoid hemorrhage. ( Commichau, C; Connolly, ES; Du, Y; Fitzsimmons, BF; Kreiter, KT; Lavine, SD; Mayer, SA; Naidech, A; Parra, A, 2005) |
| "It is suggested that milrinone was effective and safe for the treatment of cerebral vasospasm after subarachnoid hemorrhage in the patients in this series." | 3.71 | Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: report of seven cases. ( Arakawa, Y; Goto, Y; Hojo, M; Ishii, A; Kikuta, K; Yamagata, S, 2001) |
| "Several methods have been used to treat cerebral vasospasm, which is a major cause of morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage (SAH)." | 2.76 | Angiographic evaluation of the effect of intra-arterial milrinone therapy in patients with vasospasm from aneurysmal subarachnoid hemorrhage. ( Deus-Silva, L; dos Santos, MP; Lum, C; Shankar, JJ, 2011) |
| "Delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage continues to be associated with high levels of morbidity and mortality." | 2.72 | Treatment of Subarachnoid Hemorrhage-associated Delayed Cerebral Ischemia With Milrinone: A Review and Proposal. ( Abulhasan, YB; Angle, MR; Aziz-Sultan, MA; Bernier, TD; Chung, DY; Dasenbrock, H; Du, R; Feske, S; Henderson, GV; Izzy, S; Leslie-Mazwi, TM; Nelson, SE; Patel, N; Schontz, MJ, 2021) |
| "Delayed cerebral ischemia (DCI) is a complication of aneurysmal subarachnoid hemorrhage (aSAH) and is associated with significant morbidity and mortality." | 1.91 | Subarachnoid Hemorrhage, Delayed Cerebral Ischemia, and Milrinone Use in Canada. ( Almojuela, A; Bokhari, R; Christie, SD; Duda, T; Eagles, ME; Elkaim, LM; Iorio-Morin, C; Kameda-Smith, MM; Lownie, SP; MacLean, MA; Persad, ARL; Rizzuto, MA; Teitelbaum, J, 2023) |
| "These findings indicate that cerebral vasospasm exists in pediatrics, particularly after nontraumatic SAH." | 1.72 | Cerebral vasospasm in children with subarachnoid hemorrhage: frequency, diagnosis, and therapeutic management. ( Baud, C; Desrumaux, A; Evain, JN; Francony, G; Isola, C; Millet, A; Mortamet, G; Payen, JF; Wroblewski, I, 2022) |
| "OBJECTIVE Delayed cerebral ischemia (DCI) is an important complication after aneurysmal subarachnoid hemorrhage (aSAH)." | 1.48 | Effect of intrathecal milrinone injection via lumbar catheter on delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Chin, M; Fukuda, H; Handa, A; Koyanagi, M; Kurosaki, Y; Lo, B; Sadamasa, N; Uezato, M; Yamagata, S, 2018) |
| "Background Cerebral vasospasm (CV) is a major cause of delayed morbidity and mortality in patients with subarachnoid hemorrhage (SAH)." | 1.46 | Higher dose intra-arterial milrinone and intra-arterial combined milrinone-nimodipine infusion as a rescue therapy for refractory cerebral vasospasm. ( Dogan, R; Duman, E; Fırat, A; Karakoç, F; Pinar, HU; Yıldırım, E, 2017) |
| "Although cerebral vasospasm remains a common complication of SAH and constitutes an important predictor of outcome, in the setting of PNSAH, it is extremely rare." | 1.46 | Basilar artery vasospasm after pretuncal non-aneurysmal subarachnoid hemorrhage responding to milrinone. ( Alamri, AS; Alturki, AY; Badawy, MM; Lo, BW, 2017) |
| "Acute cerebral hypoperfusion following subarachnoid hemorrhage (SAH) is highly related to the pathogenesis of delayed cerebral ischemia (DCI), but the therapeutic option is poorly available." | 1.46 | Neurocardiac protection with milrinone for restoring acute cerebral hypoperfusion and delayed ischemic injury after experimental subarachnoid hemorrhage. ( Ishikawa, T; Mutoh, T; Nakamura, K; Sasaki, K; Taki, Y; Tatewaki, Y, 2017) |
| "Milrinone was recently suggested as an invasive VSP treatment option." | 1.42 | Repeated combined endovascular therapy with milrinone and nimodipine for the treatment of severe vasospasm: preliminary results. ( Karaic, R; Kleinpeter, G; Krafft, P; Loyoddin, M; Sherif, C; Tscholakoff, D; Valentin, A; Wambacher, B, 2015) |
| "DIND, delayed cerebral infarction (DCI), and modified Rankin scale at 3 months after SAH were used for the assessment of outcome." | 1.40 | Milrinone via lumbar subarachnoid catheter for vasospasm after aneurysmal subarachnoid hemorrhage. ( Chin, M; Narumi, O; Sadamasa, N; Yamagata, S; Yoshida, K, 2014) |
| "For the treatment of cerebral vasospasm, current therapies have focused on increasing blood flow through blood pressure augmentation, hypervolemia, the use of intra-arterial vasodilators, and angioplasty of proximal cerebral vessels." | 1.38 | Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol. ( Angle, M; Cardoso, M; del Pilar Cortés, M; Lannes, M; Teitelbaum, J, 2012) |
| "Milrinone was injected intracisternally (0." | 1.36 | Effect of vasodilation by milrinone, a phosphodiesterase III inhibitor, on vasospastic arteries after a subarachnoid hemorrhage in vitro and in vivo: effectiveness of cisternal injection of milrinone. ( Date, I; Hishikawa, T; Iseda, K; Manabe, H; Nishiguchi, M; Ono, S, 2010) |
| "Attempts to reverse cerebral vasospasm (CVS) after aneurysmal subarachnoid hemorrhage (aSAH) rely on a limited number of treatments." | 1.35 | Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. ( Cholley, BP; Fraticelli, AT; Losser, MR; Payen, D; Saint Maurice, JP, 2008) |
| "Treatment with milrinone caused no significant changes in systemic hemodynamics." | 1.30 | Prevention of chronic cerebral vasospasm in dogs with milrinone. ( Ayzman, I; Chyatte, D; Hahn, JF; Jones, SC; Khajavi, K; Levy, JH; Prayson, RA; Shearer, D; Skibinski, CI, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.56) | 18.2507 |
| 2000's | 5 (12.82) | 29.6817 |
| 2010's | 20 (51.28) | 24.3611 |
| 2020's | 13 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lakhal, K | 3 |
| Hivert, A | 1 |
| Rozec, B | 1 |
| Cadiet, J | 1 |
| Abulhasan, YB | 2 |
| Ortiz Jimenez, J | 1 |
| Teitelbaum, J | 4 |
| Angle, MR | 2 |
| Isola, C | 1 |
| Evain, JN | 1 |
| Francony, G | 2 |
| Baud, C | 1 |
| Millet, A | 1 |
| Desrumaux, A | 1 |
| Wroblewski, I | 1 |
| Payen, JF | 2 |
| Mortamet, G | 1 |
| Robert-Edan, V | 2 |
| Rodie-Talbere, PA | 1 |
| Ambrosi, X | 1 |
| Fresco, M | 1 |
| Mahajan, C | 1 |
| Shukla, RK | 1 |
| Kapoor, I | 1 |
| Prabhakar, H | 1 |
| Steiger, HJ | 1 |
| Ensner, R | 1 |
| Andereggen, L | 1 |
| Remonda, L | 1 |
| Berberat, J | 1 |
| Marbacher, S | 1 |
| Eagles, ME | 1 |
| MacLean, MA | 1 |
| Kameda-Smith, MM | 1 |
| Duda, T | 1 |
| Persad, ARL | 1 |
| Almojuela, A | 1 |
| Bokhari, R | 1 |
| Iorio-Morin, C | 1 |
| Elkaim, LM | 1 |
| Rizzuto, MA | 1 |
| Lownie, SP | 1 |
| Christie, SD | 1 |
| Kotwal, A | 1 |
| Ramalingaiah, AH | 1 |
| Shukla, D | 1 |
| Radhakrishnan, M | 2 |
| Konar, SK | 1 |
| Srinivasaiah, B | 1 |
| Chakrabarti, D | 1 |
| Sundaram, M | 1 |
| Deem, S | 1 |
| Livesay, S | 1 |
| Treggiari, MM | 1 |
| Cottenceau, V | 1 |
| Poutier, B | 1 |
| Gariel, F | 1 |
| Sauvage, N | 1 |
| Petit, L | 1 |
| Carrie, C | 1 |
| Biais, M | 2 |
| Lucas, L | 1 |
| de Courson, H | 1 |
| Marnat, G | 1 |
| Sibon, I | 1 |
| Bernier, TD | 1 |
| Schontz, MJ | 1 |
| Izzy, S | 1 |
| Chung, DY | 1 |
| Nelson, SE | 1 |
| Leslie-Mazwi, TM | 1 |
| Henderson, GV | 1 |
| Dasenbrock, H | 1 |
| Patel, N | 1 |
| Aziz-Sultan, MA | 1 |
| Feske, S | 1 |
| Du, R | 1 |
| Castle-Kirszbaum, M | 1 |
| Lai, L | 1 |
| Maingard, J | 1 |
| Asadi, H | 1 |
| Danks, RA | 1 |
| Goldschlager, T | 1 |
| Chandra, RV | 1 |
| Alturki, AY | 1 |
| Alamri, AS | 1 |
| Badawy, MM | 1 |
| Lo, BW | 1 |
| Duman, E | 1 |
| Karakoç, F | 1 |
| Pinar, HU | 1 |
| Dogan, R | 1 |
| Fırat, A | 1 |
| Yıldırım, E | 1 |
| Crespy, T | 1 |
| Heintzelmann, M | 1 |
| Chiron, C | 1 |
| Vinclair, M | 1 |
| Tahon, F | 1 |
| Anand, S | 1 |
| Goel, G | 1 |
| Gupta, V | 1 |
| Sadamasa, N | 2 |
| Yoshida, K | 1 |
| Narumi, O | 1 |
| Chin, M | 2 |
| Yamagata, S | 5 |
| Sherif, C | 1 |
| Wambacher, B | 1 |
| Loyoddin, M | 1 |
| Karaic, R | 1 |
| Krafft, P | 1 |
| Valentin, A | 1 |
| Tscholakoff, D | 1 |
| Kleinpeter, G | 1 |
| Mittal, M | 1 |
| UmamaheswaraRao, GS | 1 |
| Lannes, M | 2 |
| Zeiler, F | 1 |
| Guichon, C | 1 |
| Mutoh, T | 4 |
| Nakamura, K | 2 |
| Yamamoto, Y | 1 |
| Tsuru, Y | 1 |
| Tsubone, H | 1 |
| Ishikawa, T | 2 |
| Taki, Y | 2 |
| Sasaki, K | 1 |
| Tatewaki, Y | 1 |
| Vimala, S | 1 |
| Madhusudhan, S | 1 |
| Sahoo, BK | 1 |
| Koyanagi, M | 1 |
| Fukuda, H | 1 |
| Lo, B | 1 |
| Uezato, M | 1 |
| Kurosaki, Y | 1 |
| Handa, A | 1 |
| Nishiguchi, M | 1 |
| Ono, S | 1 |
| Iseda, K | 1 |
| Manabe, H | 1 |
| Hishikawa, T | 1 |
| Date, I | 1 |
| Pierot, L | 1 |
| Aggour, M | 1 |
| Moret, J | 1 |
| Schmidt, U | 1 |
| Bittner, E | 1 |
| Pivi, S | 1 |
| Marota, JJ | 1 |
| Shankar, JJ | 1 |
| dos Santos, MP | 1 |
| Deus-Silva, L | 1 |
| Lum, C | 1 |
| Chai, TS | 1 |
| Charchaflieh, J | 1 |
| Svyatets, M | 1 |
| del Pilar Cortés, M | 1 |
| Cardoso, M | 1 |
| Angle, M | 1 |
| Baumann, A | 1 |
| Derelle, AL | 1 |
| Mertes, PM | 1 |
| Audibert, G | 1 |
| Goto, Y | 3 |
| Arakawa, Y | 2 |
| Kikuta, K | 2 |
| Hojo, M | 2 |
| Nozaki, K | 1 |
| Hashimoto, N | 1 |
| Naidech, A | 1 |
| Du, Y | 1 |
| Kreiter, KT | 1 |
| Parra, A | 1 |
| Fitzsimmons, BF | 1 |
| Lavine, SD | 1 |
| Connolly, ES | 1 |
| Mayer, SA | 1 |
| Commichau, C | 1 |
| Fraticelli, AT | 1 |
| Cholley, BP | 1 |
| Losser, MR | 1 |
| Saint Maurice, JP | 1 |
| Payen, D | 1 |
| Khajavi, K | 1 |
| Ayzman, I | 1 |
| Shearer, D | 1 |
| Jones, SC | 1 |
| Levy, JH | 1 |
| Prayson, RA | 1 |
| Skibinski, CI | 1 |
| Hahn, JF | 1 |
| Chyatte, D | 1 |
| Ishii, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage[NCT02712788] | Phase 2 | 4 participants (Actual) | Interventional | 2016-04-18 | Terminated (stopped due to Completion not feasible due to lack of eligible subjects.) | ||
| The Intra-arterial Vasospasm Trial(iVAST)- A Multi-center Randomized Study[NCT01996436] | Phase 4 | 330 participants (Anticipated) | Interventional | 2016-08-29 | Recruiting | ||
| Cerebral Aneurysms: a Retrospective Study on the Experience in Our Hospital With a Comparative Analysis Between the Different Techniques Used in Its Treatment[NCT04792944] | 247 participants (Actual) | Observational | 2007-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reported as number for each subject and then will look statistically to see if there is a difference between the active arm and the placebo arm. The Modified Rankin scale is Scored as follows: 0 = No symptoms, 1 = No significant disability. Able to carry out all usual activities, despite some symptoms, 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent, 6 = Death. Higher scores indicate worse outcome. (NCT02712788)
Timeframe: 6 months
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 1.5 |
Reported as number for each subject and then will look statistically to see if there is a difference between the active arm and the placebo arm. THe Modified Rankin Scale is Scored as follows: 0 = No symptoms, 1 = No significant disability. Able to carry out all usual activities, despite some symptoms, 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent, 6 = Death. Higher scores indicate worse outcome. (NCT02712788)
Timeframe: 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 2 |
4 reviews available for milrinone and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Treatment of Subarachnoid Hemorrhage-associated Delayed Cerebral Ischemia With Milrinone: A Review and Proposal.
Topics: Brain Ischemia; Humans; Milrinone; Multicenter Studies as Topic; Randomized Controlled Trials as Top | 2021 |
Intravenous milrinone for treatment of delayed cerebral ischaemia following subarachnoid haemorrhage: a pooled systematic review.
Topics: Brain Ischemia; Cerebral Infarction; Female; Humans; Male; Middle Aged; Milrinone; Pharmaceutical Pr | 2021 |
The Use of Milrinone in Patients with Delayed Cerebral Ischemia Following Subarachnoid Hemorrhage: A Systematic Review.
Topics: Brain Ischemia; Humans; Milrinone; Subarachnoid Hemorrhage; Vasodilator Agents | 2017 |
Vasospasm after aneurysmal subarachnoid hemorrhage: recent advances in endovascular management.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angioplasty, Balloon; Critical Care; Endovascular Pro | 2010 |
2 trials available for milrinone and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Angiographic evaluation of the effect of intra-arterial milrinone therapy in patients with vasospasm from aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Cerebral Angiography; Female; Humans; Injections, Intra-Arterial; Male; Middle Aged; Mi | 2011 |
Milrinone reduces cerebral vasospasm after subarachnoid hemorrhage of WFNS grade IV or V.
Topics: Adult; Aged; Aged, 80 and over; Cisterna Magna; Female; Humans; Male; Middle Aged; Milrinone; Radiog | 2004 |
33 other studies available for milrinone and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Induced Hypertension or Intravenous Milrinone for Cerebral Vasospasm: Why Choose?
Topics: Cerebral Angiography; Humans; Hypertension; Milrinone; Subarachnoid Hemorrhage; Vasospasm, Intracran | 2021 |
Role of Induced Hypertension and Intravenous Milrinone After Aneurysmal Subarachnoid Hemorrhage: Is it Time to Shift the Paradigm?
Topics: Cerebral Angiography; Humans; Hypertension; Milrinone; Subarachnoid Hemorrhage; Vasospasm, Intracran | 2021 |
Cerebral vasospasm in children with subarachnoid hemorrhage: frequency, diagnosis, and therapeutic management.
Topics: Adult; Child; Humans; Milrinone; Retrospective Studies; Subarachnoid Hemorrhage; Ultrasonography, Do | 2022 |
Intravenous Milrinone for Cerebral Vasospasm: Here Comes the Sun?
Topics: Administration, Intravenous; Cerebral Angiography; Humans; Milrinone; Subarachnoid Hemorrhage; Vasos | 2022 |
Intravenous Milrinone for Cerebral Vasospasm in Subarachnoid Hemorrhage.
Topics: Cerebral Angiography; Humans; Milrinone; Subarachnoid Hemorrhage; Vasodilator Agents; Vasospasm, Int | 2022 |
Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine-based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage.
Topics: Brain Ischemia; Cerebral Infarction; Hemodynamics; Humans; Hypertension; Milrinone; Nimodipine; Nore | 2022 |
Subarachnoid Hemorrhage, Delayed Cerebral Ischemia, and Milrinone Use in Canada.
Topics: Brain Ischemia; Canada; Cerebral Infarction; Cross-Sectional Studies; Humans; Milrinone; Subarachnoi | 2023 |
Role of Nimodipine and Milrinone in Delayed Cerebral Ischemia.
Topics: Brain Ischemia; Cerebral Infarction; Humans; Milrinone; Nimodipine; Subarachnoid Hemorrhage; Vasospa | 2022 |
Response to "Treating Vasospasm with IV Milrinone: RELAX (the Vessel) or DON'T DO IT!"
Topics: Humans; Milrinone; Subarachnoid Hemorrhage; Vasodilator Agents | 2023 |
Treating Vasospasm with IV Milrinone: Relax (The Vessel) or Don't Do It!
Topics: Humans; Milrinone; Subarachnoid Hemorrhage; Vasodilator Agents; Vasospasm, Intracranial | 2023 |
May levosimendan be safe and effective in refractory vasospasm despite adequate treatment with repeated angiography and milrinone infusion after subarachnoid haemorrhage?
Topics: Aneurysm, Ruptured; Cardiotonic Agents; Cerebral Angiography; Cerebrospinal Fluid Leak; Computed Tom | 2019 |
Intravenous milrinone in posterior reversible Leucoencephalopathy Syndrome.
Topics: Administration, Intravenous; Humans; Milrinone; Posterior Leukoencephalopathy Syndrome; Subarachnoid | 2020 |
Basilar artery vasospasm after pretuncal non-aneurysmal subarachnoid hemorrhage responding to milrinone.
Topics: Adult; Basilar Artery; Cerebral Angiography; Female; Humans; Milrinone; Subarachnoid Hemorrhage; Tom | 2017 |
Higher dose intra-arterial milrinone and intra-arterial combined milrinone-nimodipine infusion as a rescue therapy for refractory cerebral vasospasm.
Topics: Angiography, Digital Subtraction; Cerebral Angiography; Computed Tomography Angiography; Drug Therap | 2017 |
Which Protocol for Milrinone to Treat Cerebral Vasospasm Associated With Subarachnoid Hemorrhage?
Topics: Adult; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Milrinone; Retrospective Studie | 2019 |
Continuous intra-arterial dilatation with nimodipine and milrinone for refractory cerebral vasospasm.
Topics: Angioplasty, Balloon; Cerebral Angiography; Dilatation; Drug Resistance; Female; Humans; Infusions, | 2014 |
Milrinone via lumbar subarachnoid catheter for vasospasm after aneurysmal subarachnoid hemorrhage.
Topics: Aged; Cerebral Angiography; Cerebral Infarction; Female; Humans; Infusions, Spinal; Lumbar Vertebrae | 2014 |
Repeated combined endovascular therapy with milrinone and nimodipine for the treatment of severe vasospasm: preliminary results.
Topics: Adult; Combined Modality Therapy; Endovascular Procedures; Female; Follow-Up Studies; Humans; Male; | 2015 |
Management of catecholamine-induced stunned myocardium--a case report.
Topics: Blood Pressure; Cardiotonic Agents; Catecholamines; Dobutamine; Dopamine; Female; Fluid Therapy; Hea | 2015 |
Acute cardiac support with intravenous milrinone promotes recovery from early brain injury in a murine model of severe subarachnoid haemorrhage.
Topics: Administration, Intravenous; Animals; Brain Injuries; Brain Ischemia; Cerebrovascular Circulation; D | 2017 |
Neurocardiac protection with milrinone for restoring acute cerebral hypoperfusion and delayed ischemic injury after experimental subarachnoid hemorrhage.
Topics: Animals; Brain Ischemia; Cardiotonic Agents; Cerebral Cortex; Echocardiography, Doppler; Heart; Male | 2017 |
Life-threatening Tachyarrhythmia Following Intra-Arterial Milrinone for Cerebral Vasospasm.
Topics: Adult; Electrocardiography; Humans; Male; Milrinone; Postoperative Complications; Subarachnoid Hemor | 2018 |
Effect of intrathecal milrinone injection via lumbar catheter on delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
Topics: Aged; Brain Ischemia; Catheters; Female; Humans; Injections, Spinal; Male; Middle Aged; Milrinone; S | 2018 |
Effect of vasodilation by milrinone, a phosphodiesterase III inhibitor, on vasospastic arteries after a subarachnoid hemorrhage in vitro and in vivo: effectiveness of cisternal injection of milrinone.
Topics: Angiography; Animals; Basilar Artery; Cyclic AMP; Disease Models, Animal; Dogs; Female; Injections, | 2010 |
Hemodynamic management and outcome of patients treated for cerebral vasospasm with intraarterial nicardipine and/or milrinone.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Calcium Channel Blockers; Drug Therapy, Combination; | 2010 |
Pulmonary hypertension in a patient with subarachnoid hemorrhage.
Topics: Cardiotonic Agents; Coronary Angiography; Echocardiography; Embolization, Therapeutic; Humans; Hyper | 2011 |
Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol.
Topics: Adult; Aged; Cerebral Angiography; Cerebrovascular Circulation; Critical Care; Female; Humans; Infus | 2012 |
Seeking new approaches: milrinone in the treatment of cerebral vasospasm.
Topics: Female; Humans; Male; Milrinone; Subarachnoid Hemorrhage; Vasodilator Agents; Vasospasm, Intracrania | 2012 |
[Differences in outcome in patients with poor grade subarachnoid hemorrhage (WFNS grade IV and V): according to the perioperative management against vasospasm].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Female; Glasgow Coma Scale; Humans; Male; Midd | 2004 |
Dobutamine versus milrinone after subarachnoid hemorrhage.
Topics: Adrenergic beta-Agonists; Adult; Dobutamine; Female; Humans; Male; Middle Aged; Milrinone; Myocardia | 2005 |
Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Angioplasty; Cerebral Angiography; Female; Heart Rate; Humans; Infusions, Intravenous; | 2008 |
Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Angioplasty; Cerebral Angiography; Female; Heart Rate; Humans; Infusions, Intravenous; | 2008 |
Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Angioplasty; Cerebral Angiography; Female; Heart Rate; Humans; Infusions, Intravenous; | 2008 |
Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Angioplasty; Cerebral Angiography; Female; Heart Rate; Humans; Infusions, Intravenous; | 2008 |
Prevention of chronic cerebral vasospasm in dogs with milrinone.
Topics: Animals; Cerebral Angiography; Dogs; Hemodynamics; Ischemic Attack, Transient; Milrinone; Phosphodie | 1997 |
Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: report of seven cases.
Topics: Adult; Aged; Blood Flow Velocity; Cerebral Angiography; Dose-Response Relationship, Drug; Drug Admin | 2001 |